Terns Pharmaceuticals Announces Positive Results from Phase 1 Study of TERN-601 at ADA Scientific Sessions, Phase 2 Data Expected by End of 2025

Reuters

06-24

Terns Pharmaceuticals Announces Positive Results from Phase 1 Study of TERN-601 at ADA Scientific Sessions, Phase 2 Data Expected by End of 2025

Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced positive data from its Phase 1 study of TERN-601, a novel once-daily oral GLP-1R agonist for the treatment of obesity. The results will be highlighted at the American Diabetes Association's 85th Scientific Sessions, held from June 20-23, 2025, in Chicago, IL. The Phase 1 study demonstrated a differentiated profile for TERN-601, with topline data initially reported in September 2024. Additionally, the company has completed enrollment for its Phase 2 FALCON clinical trial, with 12-week data expected in the fourth quarter of 2025. The trial aims to assess TERN-601's competitive weight loss efficacy, safety, tolerability, and dosing simplicity among GLP-1R agonist therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483096-en) on June 23, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545447501"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545447501\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545447501?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545447501","market":"fut","top_or_hot":-1,"title":"Terns Pharmaceuticals Announces Positive Results from Phase 1 Study of TERN-601 at ADA Scientific Sessions, Phase 2 Data Expected by End of 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Terns Pharmaceuticals Announces Positive Results from Phase 1 Study of TERN-601 at ADA Scientific Sessions, Phase 2 Data Expected by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced positive data from its Phase 1 study of TERN-601, a novel once-daily oral GLP-1R agonist for the treatment of obesity. The results will be highlighted at the American Diabetes Association's 85th Scientific Sessions, held from June 20-23, 2025, in Chicago, IL. The Phase 1 study demonstrated a differentiated profile for TERN-601, with topline data initially reported in September 2024. Additionally, the company has completed enrollment for its Phase 2 FALCON clinical trial, with 12-week data expected in the fourth quarter of 2025. The trial aims to assess TERN-601's competitive weight loss efficacy, safety, tolerability, and dosing simplicity among GLP-1R agonist therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483096-en) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Terns Pharmaceuticals Announces Positive Results from Phase 1 Study of TERN-601 at ADA Scientific Sessions, Phase 2 Data Expected by End of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTerns Pharmaceuticals Announces Positive Results from Phase 1 Study of TERN-601 at ADA Scientific Sessions, Phase 2 Data Expected by End of 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-24 04:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Terns Pharmaceuticals Announces Positive Results from Phase 1 Study of TERN-601 at ADA Scientific Sessions, Phase 2 Data Expected by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced positive data from its Phase 1 study of TERN-601, a novel once-daily oral GLP-1R agonist for the treatment of obesity. The results will be highlighted at the American Diabetes Association's 85th Scientific Sessions, held from June 20-23, 2025, in Chicago, IL. The Phase 1 study demonstrated a differentiated profile for TERN-601, with topline data initially reported in September 2024. Additionally, the company has completed enrollment for its Phase 2 FALCON clinical trial, with 12-week data expected in the fourth quarter of 2025. The trial aims to assess TERN-601's competitive weight loss efficacy, safety, tolerability, and dosing simplicity among GLP-1R agonist therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483096-en) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL6nLpFl:1","article_id":"2545447501","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545447501","pubTimestamp":1750709278,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Terns Pharmaceuticals Announces Positive Results from Phase 1 Study of TERN-601 at ADA Scientific Sessions, Phase 2 Data Expected by End of 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on June 23, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4007":"制药","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","TERN":"Terns Pharmaceuticals, Inc.","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Terns Pharmaceuticals在ADA Scientific Sessions上宣布TERN-601 1期研究的积极结果，2期数据预计将于2025年底公布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"TERN":0.9},"content_text":"Terns Pharmaceuticals Announces Positive Results from Phase 1 Study of TERN-601 at ADA Scientific Sessions, Phase 2 Data Expected by End of 2025\n    \n\n        Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced positive data from its Phase 1 study of TERN-601, a novel once-daily oral GLP-1R agonist for the treatment of obesity. The results will be highlighted at the American Diabetes Association's 85th Scientific Sessions, held from June 20-23, 2025, in Chicago, IL. The Phase 1 study demonstrated a differentiated profile for TERN-601, with topline data initially reported in September 2024. Additionally, the company has completed enrollment for its Phase 2 FALCON clinical trial, with 12-week data expected in the fourth quarter of 2025. The trial aims to assess TERN-601's competitive weight loss efficacy, safety, tolerability, and dosing simplicity among GLP-1R agonist therapies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483096-en) on June 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}